Welcome to our dedicated page for GCAND SEC filings (Ticker: GCAND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GCAND's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GCAND's regulatory disclosures and financial reporting.
The Greater Cannabis Company, Inc. reports unaudited results for the quarter ended March 31, 2026, with no revenue and a net loss of $33,376. Operating expenses fell to $33,376 from $43,536 a year earlier, mainly from lower stock-based and other operating costs.
Cash was only $1,439 against current liabilities of $776,464, resulting in a stockholders’ deficit of $775,025. Management explicitly concludes there is substantial doubt about the company’s ability to continue as a going concern through March 2027 without new funding.
The company continues to pursue development of a cannabinoid therapeutic licensed from Shaare Zedek Scientific Ltd., with Phase II clinical work dependent on securing specialized API and additional capital. A 1-for-1,500 reverse stock split and creation of super-voting Series B preferred shares have centralized voting control while leaving 944,935 common shares outstanding as of May 6, 2026.
The Greater Cannabis Company, Inc. reports unaudited results for the quarter ended March 31, 2026, with no revenue and a net loss of $33,376. Operating expenses fell to $33,376 from $43,536 a year earlier, mainly from lower stock-based and other operating costs.
Cash was only $1,439 against current liabilities of $776,464, resulting in a stockholders’ deficit of $775,025. Management explicitly concludes there is substantial doubt about the company’s ability to continue as a going concern through March 2027 without new funding.
The company continues to pursue development of a cannabinoid therapeutic licensed from Shaare Zedek Scientific Ltd., with Phase II clinical work dependent on securing specialized API and additional capital. A 1-for-1,500 reverse stock split and creation of super-voting Series B preferred shares have centralized voting control while leaving 944,935 common shares outstanding as of May 6, 2026.
The Greater Cannabis Company, Inc. reported a full-year 2025 net loss of $331,612 on $0 in revenue, similar to 2024. Operating expenses rose to $183,005 from $156,276, reflecting ongoing development activity without commercial sales.
Cash declined to $815 at December 31, 2025, against current liabilities of $742,464, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management is focused on a licensed cannabinoid therapy from Shaare Zedek Scientific and plans a Phase II clinical trial once specialized API is sourced and additional funding is raised. During 2025 the company completed a 1-for-1,500 reverse stock split and created Series B Preferred Shares, giving its CEO majority voting control while common shares outstanding reached 944,935 as of March 16, 2026.
The Greater Cannabis Company, Inc. reported a full-year 2025 net loss of $331,612 on $0 in revenue, similar to 2024. Operating expenses rose to $183,005 from $156,276, reflecting ongoing development activity without commercial sales.
Cash declined to $815 at December 31, 2025, against current liabilities of $742,464, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management is focused on a licensed cannabinoid therapy from Shaare Zedek Scientific and plans a Phase II clinical trial once specialized API is sourced and additional funding is raised. During 2025 the company completed a 1-for-1,500 reverse stock split and created Series B Preferred Shares, giving its CEO majority voting control while common shares outstanding reached 944,935 as of March 16, 2026.